Overview
Urinary tract infections (UTIs) are among the most common bacterial infections treated in medical practice. Yet traditional urine cultures often miss organisms, delay treatment decisions, or fail to identify antibiotic resistance.
Chemisys Molecular UTI testing uses advanced PCR technology to detect pathogens quickly and accurately — helping providers treat with confidence. Traditional culture methods require 24–72 hours, offer limited organism detection, and provide no early insight into resistance markers. Delayed or incomplete results can lead to empiric broad-spectrum antibiotic use, persistent infections, recurrent UTIs, and increased antibiotic resistance.
Our PCR-based molecular UTI panel delivers rapid turnaround, higher sensitivity and specificity, detection of difficult-to-grow organisms, identification of antibiotic resistance genes, and clear, actionable reporting — moving providers from guesswork to precision therapy.
Why it matters
Clinical value
Improved patient care
Targeted antibiotic selection reduces treatment failure and delivers better outcomes for recurrent UTI patients.
Antibiotic stewardship
Avoid unnecessary broad-spectrum antibiotics and support responsible prescribing practices.
Practice efficiency
Faster clinical decisions, reduced callbacks and repeat visits, and clear easy-to-read reports.
Explains persistent symptoms
Expanded pathogen detection helps explain persistent symptoms when cultures return negative.
What's included
Capabilities
- PCR-based molecular pathogen detection — faster than traditional culture
- Detection of common uropathogens and fastidious or atypical organisms
- Polymicrobial infection identification
- Key antibiotic resistance gene detection
- Urine culture with pathogen identification
- Antibiotic sensitivity panels
Applications
Clinical settings we serve
- Primary Care
- Urology
- Women's Health
- Urgent Care
- Long-Term Care
- Patients with recurrent or chronic UTIs
Related services